Therapy News and Research

RSS

$FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease$

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell’s Investigational New Drug application for the company’s lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease.

30 Jun 2015

Study may lead to better treatments for children with neuroblastoma

Researchers studying the pediatric cancer neuroblastoma have detailed how cancer-driving mutations evolve during chemotherapy, and they hope to exploit this knowledge to design better treatments for children.

30 Jun 2015

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

SillaJen, Inc., a private clinical-stage biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, today announced a publication of data demonstrating that in a Phase Ib trial of Pexa-Vec, patients received multiple bi-weekly doses of its lead product Pexa-Vec, representing the first report of multiple intravenous administrations of an oncolytic vaccinia.

29 Jun 2015

Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

According to analysis from business intelligence provider GBI Research - Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - the value of the global Glioblastoma Multiforme (GBM) treatment market will expand at a rapid Compound Annual Growth Rate (CAGR) of 10.9%, from $301 million in 2013 to $623 million by 2020.

29 Jun 2015

People with specific gene variant at greater risk of developing depressions

People born with a particular gene variant have a greater risk of developing depressions, a recent study from the Department of Psychology at The University of Oslo shows.

29 Jun 2015

Researchers develop world's first prognosis scoring system for life expectancy of patients in hospitals

Researchers at the MedUni Vienna's University Department of Anaesthetics, General Intensive Care Medicine and Pain Therapy, the University Department of Internal Medicine III and the Centre for Medical Statistics, Information Technology and Intelligent Systems have developed the world's first prognosis scoring system (PANDORA score) for hospital patients and their life expectancy within the next 30 days.

29 Jun 2015

Two physician-scientists in search for better Alzheimer's disease treatment

Two of the nation's leading physician-scientists in the search to better understand and treat Alzheimer's disease - William Mobley, MD, PhD, and Michael Rafii, MD, PhD - have been named interim co-directors of the Alzheimer's Disease Cooperative Study (ADCS), a major initiative formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California, San Diego.

27 Jun 2015

Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden.

27 Jun 2015

NIDA announces recipients of Avenir Award programs for HIV/AIDS, genetics or epigenetics research

The National Institute on Drug Abuse today announced the first six recipients of its two newly developed Avenir Award programs for HIV/AIDS and genetics or epigenetics research. The Avenir (meaning "future" in French) Awards support early stage investigators who propose highly innovative studies. The six scientists will each receive up to $300,000 per year for five years to support their research.

27 Jun 2015

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma.

27 Jun 2015

Discovery sheds light on how the Hippo pathway maintains cellular balance

Researchers at University of California, San Diego School of Medicine have discovered a self-regulating loop in the Hippo pathway, a signaling channel garnering increased attention from cancer researchers due to its role in controlling organ size, cell proliferation and cell death.

27 Jun 2015

No overall survival benefit for bevacizumab in ovarian cancer

Addition of bevacizumab to first-line platinum-based chemotherapy does not improve overall survival in women with ovarian cancer, according to the mature data of the ICON7 trial.

26 Jun 2015

Partial breast radiation after lumpectomy does not increase cancer recurrence

A new study by UCLA scientists has found that women diagnosed with breast cancer and treated with a one-week regimen of partial breast radiation after the surgical removal of the tumor, or lumpectomy, saw no increase in cancer recurrence or difference in cosmetic outcomes compared to women who received radiation of the entire breast for a period of up to six weeks after surgery.

26 Jun 2015

Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Mary Ann Liebert, publisher of the newly launched peer-reviewed open access journal Cannabis and Cannabinoid Research, strongly supports President Obama's statement that "...carefully prescribed medical use of marijuana may in fact be appropriate and we should follow the science as opposed to ideology on this issue," when asked about a pending Senate bill seeking to change federal law regarding state-legalized medical marijuana programs.

26 Jun 2015

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline.

26 Jun 2015

Innovative gene transfer-based treatment for kids with giant axonal neuropathy

University of North Carolina School of Medicine researchers have developed an innovative, experimental gene transfer-based treatment for children with giant axonal neuropathy (GAN).

26 Jun 2015

Potential new class of drugs lessen neurodegeneration in rat model of Parkinson's disease

The first test in a mammalian model of a potential new class of drugs to treat Parkinson's disease shows abatement of neurodegeneration in the brains of test rats and no significant toxicities, University of Alabama at Birmingham and Pfizer Inc. researchers report online in The Journal of Biological Chemistry.

26 Jun 2015

Lamont R Jones receives 2015 Research Scholar Award to study pathogenesis of keloids

Lamont R Jones, M.D., vice chair of the Department of Otolaryngology-Head & Neck Surgery at Henry Ford Hospital, received the 2015 Research Scholar Award from the Educational and Research Foundation for the American Academy of Facial Plastic and Reconstructive Surgery to continue his efforts to study the pathogenesis of keloids and improve understanding of how keloid scars develop.

26 Jun 2015

Unique program enhances sense of purpose and meaning in life for seniors living independently

A unique program combining a life review writing workshop with conversations between seniors and college students enhances the sense of meaning in life for older adults living independently, finds a new study by NYU's Steinhardt School of Culture, Education, and Human Development.

26 Jun 2015

New UCLA study may lead to more precise treatments for obsessive-compulsive disorder

Tens of millions of Americans -- an estimated 1 to 2 percent of the population -- will suffer at some point in their lifetimes from obsessive-compulsive disorder, a disorder characterized by recurrent, intrusive, and disturbing thoughts (obsessions), and/or stereotyped recurrent behaviors (compulsions).

26 Jun 2015

Therapy News and Research

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

Study may lead to better treatments for children with neuroblastoma

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

People with specific gene variant at greater risk of developing depressions

Researchers develop world's first prognosis scoring system for life expectancy of patients in hospitals

Two physician-scientists in search for better Alzheimer's disease treatment

Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

NIDA announces recipients of Avenir Award programs for HIV/AIDS, genetics or epigenetics research

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Discovery sheds light on how the Hippo pathway maintains cellular balance

No overall survival benefit for bevacizumab in ovarian cancer

Partial breast radiation after lumpectomy does not increase cancer recurrence

Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Innovative gene transfer-based treatment for kids with giant axonal neuropathy

Potential new class of drugs lessen neurodegeneration in rat model of Parkinson's disease

Lamont R Jones receives 2015 Research Scholar Award to study pathogenesis of keloids

Unique program enhances sense of purpose and meaning in life for seniors living independently

New UCLA study may lead to more precise treatments for obsessive-compulsive disorder

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News